| Similar Articles |
|---|
 |
Bio-IT World
January 12, 2004
Kevin Davies |
The Ultimate Platform Firm Greg Lucier on determinism in drug development at Invitrogen   |
The Motley Fool
February 7, 2008
Brian Orelli |
Invitrogen Integrates After a rough 2006 in which it struggled to integrate its acquisitions, Invitrogen used 2007 to show why it made all of its purchases. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
The Motley Fool
August 14, 2007
Brian Orelli |
Drugmaker Growth Without the FDA Do you have one of those stomachs that just can't take the ups and downs of clinical trial data and FDA approval decisions? Buy stocks in the companies that support the drug makers. |
Bio-IT World
November 2005 |
News Blast Invitrogen has acquired Quantum Dot Corp and BioPixels... CombinatoRX and Angiotech Pharmaceuticals strike an agreement... Caliper Life Sciences to close NovaScreen BioSciences... Rosetta Biosoftware and Agendia working together... |
The Motley Fool
February 15, 2007 |
A Setback at Invitrogen: Fool by Numbers The biotech released earning for the fourth-quarter 2006: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
Bio-IT World
November 14, 2003
Hoffer et al. |
Over the Rainbow Yet? Consolidation slows, valuations grow, and now there's hope for some biotech IPOs. |
BusinessWeek
March 26, 2007
Arlene Weintraub |
Biotech's Unlikely New Pal Can private equity manage its big risks and far-off returns? |
The Motley Fool
July 9, 2008
Brian Lawler |
Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests. |
The Motley Fool
May 2, 2007 |
Solid Invitrogen: Fool by Numbers The biotech released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
October 12, 2005
Carl Wherrett |
Q-Dots No More Quantum Dot sells out to Invitrogen. Will the absence of an IPO window will push other private nanotech companies to sell now rather than go through the arduous process of a public listing? |
BusinessWeek
November 6, 2006
Nichola Saminather |
Biotech's Beef There is a disconnect between what universities are teaching and what biotech wants. |
